ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

9480	Companies
185543	Keywords
117939	Articles
99384	Press releases

Home
Companies
ABIVAX

BRIEF

published on 08/13/2025 at 18:05, 3 months 23 days ago

ABIVAX: Données sur les actions et droits de vote au 31 juillet 2025

Euronext Paris Droits De Vote Biotechnologie Actions Réglementation AMF
PRESS RELEASE

published on 08/13/2025 at 18:00, 3 months 23 days ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote
ABIVAX communique le nombre total de droits de vote et d'actions conformément à la réglementation en vigueur. Abivax se focalise sur le développement de traitements thérapeutiques pour les maladies inflammatoires chroniques

Droits De Vote Actions Abivax Traitements Thérapeutiques Maladies Inflammatoires
PRESS RELEASE

published on 08/13/2025 at 18:00, 3 months 23 days ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote
ABIVAX communique le nombre d'actions composant son capital social et le nombre total de droits de vote conformément aux dispositions réglementaires

Droits De Vote Capital Social Abivax Finance Réglementaire
BRIEF

published on 07/28/2025 at 22:20, 4 months 7 days ago

Abivax Completes $747.5 Million Public Offering

Biotechnology Abivax Ulcerative Colitis Nasdaq Public Offer
BRIEF

published on 07/28/2025 at 22:20, 4 months 7 days ago

Abivax conclut une offre publique de 747,5 millions de dollars

Biotechnologie Abivax Nasdaq Rectocolite Hémorragique Offre Publique
PRESS RELEASE

published on 07/28/2025 at 22:15, 4 months 7 days ago

Abivax annonce la réalisation de son offre au public de 747,5 millions de dollars
Abivax réalise une offre publique de 747,5 millions de dollars pour financer ses activités jusqu'en 2027. Cotée en bourse à Paris et Nasdaq, elle se concentre sur les maladies inflammatoires

Financement Abivax Bourse Offre Publique Maladies Inflammatoires
PRESS RELEASE

published on 07/28/2025 at 22:15, 4 months 7 days ago

Abivax Announces Closing of $747.5 Million Public Offering
Abivax announces closing of $747.5 million public offering, enabling financing into Q4 2027 and reaching planned milestones for Ulcerative Colitis. ADSs listed on Euronext Paris and Nasdaq Global Market

Abivax Ulcerative Colitis Nasdaq Finance Public Offering
BRIEF

published on 07/25/2025 at 08:05, 4 months 11 days ago

Abivax lève 747,5 millions de dollars grâce à une offre publique d'achat (ADS)

Biotechnologie Abivax Nasdaq Augmentation De Capital Offre ADS
BRIEF

published on 07/25/2025 at 08:05, 4 months 11 days ago

Abivax Raises $747.5M Through ADS Offering

Biotechnology Abivax Nasdaq Capital Increase ADS Offering
PRESS RELEASE

published on 07/25/2025 at 08:00, 4 months 11 days ago

Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l'Offre à 747,5 M$ (637,5 M€)
Abivax annonce exercice intégral option souscription ADS supplémentaires. Produit brut Offre à 747,5 M$. Société biotechnologie spécialisée en immunothérapie. Prix offre 64,00$ par ADS. Actions admises Nasdaq et Euronext. Document relatif déposé auprès de la SEC

Biotechnologie Abivax SEC Immunothérapie Prix Offre

Accesswire

Published on 12/05/2025 at 20:25, 36 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 46 minutes ago

When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 11 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 41 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 2 hours 16 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 2 hours 3 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 2 hours 34 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 2 hours 45 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 3 hours 9 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 3 hours 15 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 3 hours 43 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 3 hours 43 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 50 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 50 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 7 hours 2 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE